PUBLIC PRESS RELEASE 17 SEPTEMBER[removed]Pres s Releas e

First Page		Document Content
Date: 2012-06-19 08:45:59 Ammine complexes Membrane biology Lipoplatin Liposome Immune system Cisplatin Apoptosis Carboplatin Nanoparticle Chemistry Biology Alkylating antineoplastic agents		PUBLIC PRESS RELEASE 17 SEPTEMBER[removed]Pres s Releas e Add to Reading List Source URL: regulon.org Download Document from Source Website File Size: 1,57 MB Share Document on Facebook

	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R, DocID: 1t7Mt - View Document
	Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in patients (pts) with recurrent platinum-sensitive ovarian cancer (OC) Roisin O’Cearbhaill1, Scott McM DocID: 1sKda - View Document
	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage D, DocID: 1pDVR - View Document
	CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for DocID: 1pDeC - View Document
	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Kotasek 3 Markman DocID: 1ji3h - View Document